Eli Lilly | Satış Brüt Kar



Gross Profit On Sales Değişiklik Tarih
AbbVie USD 10.71B 458M 2024-12
Abbott USD 6.03B 93M 2024-12
ALKERMES USD 146.5M 168.54M 2024-12
Amgen USD 5.97B 781M 2024-12
AstraZeneca USD 12.17B 1.06B 2024-12
Baxter International USD 1.02B 19M 2024-12
Biogen USD 1.87B 44.1M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Drreddys Laboratories INR 49.05B 1.28B 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.56B 57M 2024-12
Glaxosmithkline GBP 5.6B 94M 2024-12
Indivior 248M 1000K 2024-09
J&J USD 15.41B 102M 2024-12
Medtronic USD 5.52B 49M 2025-01
Merck USD 11.92B 852M 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Novartis USD 10.24B 313M 2024-12
Novo Nordisk 60B 2.22B 2024-09
Perrigo USD 385.9M 18.5M 2024-12
Pfizer USD 12.11B 718M 2024-12
Prestige Brands USD 161.05M 3.67M 2024-12
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 10.07B 2.1B 2024-09
Sanofi EUR 10.07B 2.1B 2024-09
United Therapeutics USD 660M 5.8M 2024-12
Zoetis USD 1.61B 79M 2024-12



Eli Lilly Satış Brüt Kar - Akım değerleri, tarihsel veriler, tahminler, istatistikler, grafikler ve ekonomik takvim - Mar 2025.